Townsquare Capital LLC Trims Stock Holdings in Eli Lilly and Company $LLY

Townsquare Capital LLC reduced its position in Eli Lilly and Company (NYSE:LLY) by 34.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,941 shares of the company’s stock after selling 3,080 shares during the quarter. Townsquare Capital LLC’s holdings in Eli Lilly and Company were worth $4,533,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of LLY. Sumitomo Mitsui Financial Group Inc. purchased a new stake in shares of Eli Lilly and Company during the second quarter worth about $27,000. Evolution Wealth Management Inc. bought a new position in Eli Lilly and Company in the 2nd quarter worth approximately $29,000. Steph & Co. grew its holdings in Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after buying an additional 29 shares in the last quarter. Financial Gravity Companies Inc. bought a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $31,000. Finally, Bare Financial Services Inc lifted its holdings in shares of Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after buying an additional 29 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly struck a partnership with Repertoire Immune Medicines worth up to $1.93 billion to develop therapies for multiple autoimmune diseases — expands pipeline and adds near?term R&D optionality and milestone upside. Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies
• Positive Sentiment: LLY announced a major gene?editing collaboration and licensing deal (reported ~$1.1B) with Seamless/Seamless Therapeutics to develop programmable recombinase?based and other gene?editing treatments, including hearing?loss programs — further diversifies the pipeline beyond GLP?1s. Eli Lilly (LLY) Inks $1.12 Billion Deal with ‘Gene-Editing’ Firm Seamless
• Positive Sentiment: Coverage highlights LLY’s push beyond GLP?1s into oncology and gene editing (including an AI partnership to accelerate oncology R&D), signaling new growth vectors that support higher long?term revenue potential. Eli Lilly Expands Beyond GLP 1s With Gene Editing And Oncology Bets
• Positive Sentiment: President Trump said Lilly plans to build six U.S. manufacturing plants — signals capacity expansion and potential supply resilience that investors view favorably for scaling demand. Trump says Eli Lilly to build six US plants
• Neutral Sentiment: Analyst and commentary pieces (bull case writeups) reiterate strong fundamentals and a bullish valuation thesis for LLY but are opinion?driven rather than new corporate developments. Eli Lilly and Company (LLY): A Bull Case Theory
• Neutral Sentiment: Recent earnings and sector momentum have supported LLY’s multiple; analysts expect continued earnings strength into the next report (positive fundamental backdrop but largely already priced in). Eli Lilly (LLY) Drives Q4 Gains as Pharma Fundamentals Shine Amid Sector Rotation
• Negative Sentiment: Medicare’s expanded drug?price negotiation list includes Verzenio, raising potential pricing pressure on one of Lilly’s oncology products and creating earnings risk if negotiations materially reduce net pricing. Medicare is about to start negotiating the prices of medications administered by doctors
• Negative Sentiment: Some investors sold into the news: LLY shares briefly fell after the gene?editing announcement, suggesting part of the market reaction is profit?taking or that investors wanted clearer near?term revenue visibility. Eli Lilly Stock Drops even after Signing Major $1.1 Billion Gene-Editing Partnership
• Negative Sentiment: Competitive pressure in obesity/weight?loss remains intense (Novo Nordisk is outspending Lilly on advertising), which could cap market share or force higher promotional costs. Novo Nordisk Is Spending Twice as Much as Eli Lilly (LLY) on Weight-Loss Drug Ads

Eli Lilly and Company Stock Up 0.0%

NYSE LLY opened at $1,023.81 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The firm has a market capitalization of $967.89 billion, a price-to-earnings ratio of 50.09, a PEG ratio of 0.77 and a beta of 0.35. The company has a fifty day moving average of $1,057.27 and a two-hundred day moving average of $887.02.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same period last year, the firm earned $1.18 earnings per share. Eli Lilly and Company’s revenue was up 53.9% compared to the same quarter last year. On average, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on LLY shares. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Bank of America dropped their price target on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research note on Monday, December 15th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, December 1st. Morgan Stanley increased their target price on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. Finally, National Bankshares set a $1,286.00 price target on shares of Eli Lilly and Company in a research report on Monday, December 1st. Four research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $1,173.91.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.